July 23, 2017 4:06 AM ET


Company Overview of GammaDelta Therapeutics Ltd.

Company Overview

GammaDelta Therapeutics Ltd. develops immunotherapies for cancer and other diseases. The company was founded in 2016 and is based in London, United Kingdom.

38 Jermyn Street

London,  SW1Y 6DN

United Kingdom

Founded in 2016

Key Executives for GammaDelta Therapeutics Ltd.

Chief Executive Officer
Age: 66
Founder and Director of Intellectual Property
Chief Operating Officer
Chief Scientific Officer
Compensation as of Fiscal Year 2017.

GammaDelta Therapeutics Ltd. Key Developments

Takeda Pharmaceutical and GammaDelta Therapeutics Enter into Partnership to Develop GammaDelta Therapeutics' T Cell Platform

Takeda Pharmaceutical Co. Ltd. and GammaDelta Therapeutics Ltd. have entered into partnership to develop GammaDelta Therapeutics' T cell platform, which is based on the properties of gamma delta T cells derived from human tissues. Takeda Pharma and GammaDelta Therapeutics intend to use this platform to discover and develop immunotherapies, with the aim of treating a broad range of cancers, including solid tumours, and autoinflammatory diseases. The research developed by professor Adrian Hayday and Dr. Oliver Nussbaumer at King's College London and the Francis Crick Institute, the scientific founders of GammaDelta Therapeutics, forms the basis for the development of transformational treatments for cancer and autoinflammatory diseases.

GammaDelta Therapeutics Announces Management Changes

GammaDelta Therapeutics Ltd. announced that it has expanded its leadership team with the appointments of Paolo Paoletti, MD, as Chief Executive Officer, and Natalie Mount, PhD, as Chief Scientific Officer. Most recently, Paoletti was Chief Executive Officer of Kesios Therapeutics Ltd. Natalie Mount, PhD, Chief Scientific Officer, joins GammaDelta from the Cell and Gene Therapy Catapult where she was Chief Clinical Officer, responsible for the translational, regulatory and clinical development activities. In addition, Dayle Hogg, DPhil, has joined as Chief Operating Officer having most recently worked at Kesios Therapeutics as Chief Operating Officer following his role as an Investment Manager at Touchstone Innovations. Raj Mehta, PhD, becomes Director of Intellectual Property, Alliance Management and Business Development following his role as Commercial Founder and interim CEO of GammaDelta, where he was involved in the formation of the company alongside his role as a Business Development Executive at Cancer Research Technology Ltd.

Similar Private Companies By Industry

Company Name Region
Abcellute Ltd. Europe
Abcodia Ltd. Europe
Abeterno Ltd. Europe
Abgentis Limited Europe
Achilles Therapeutics Ltd. Europe

Recent Private Companies Transactions

Private Placement
May 9, 2017
Private Placement
September 15, 2016

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States
Bertelsmann AG Europe
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact GammaDelta Therapeutics Ltd., please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.